2nd Annual Smoking Cessation 2009

Cigarette smoking is the leading source of preventable morbidity and premature mortality worldwide. - IMS Health

Where the product market is advancing in both mechanism and drug delivery, smoking cessation is and will continue to be high demand due to anti-smoking legislation and bans over the world. Nicotine addiction continues to be one of the hardest addictions to break with everyone at one time being subject to second hand smoke the strain on the healthcare systems is showing with governments investigating health education and therapies

A wider range of products are needed to meet smokers' needs and addictions. In addition revolutionary technologies are driving the way forward in creating innovative and effective solutions, new Nicotine replacement therapies, which are expected to hit the market around late 2009.

Working together the healthcare authorities and pharmaceuticals companies are striding forward in the battle of the smoking epidemic.

By attending the conference you will:
Explore the stages leading pharmaceutical companies advancing within the anti-smoking market
Discover the directions being taken to implement the dangers of Nicotine addiction in secure environments and hard to reach groups.
Examine potential market opportunities for new anti-smoking products
Gain knowledge of forthcoming treatments and future of Nicotine Replacement therapy
Asses the importance of implementing new health guidelines to educate the younger generation and passive smoking with in our worldwide communities

Key speakers
Dr Raafat Fahim, Chief Executive Officer, Nabi Biopharmaceuticals
Mark Tucker, Chief Executive Officer, G-Nostics
Dr Robert Walton, Department of Clinical Pharmacology, Oxford University
Richard Lawrence, OTC Business Line Manager, IMS Health
Lena Degling Wikingsson, Chief Executive Officer, Independent Phamaceutica
Qaim Zaidi, Ethic Strategy Coordinator, British Heart Foundation
Trevor Van Mierlo, Chief Executive Officer, V-CC Systems
Dr Martin Ledson, Consultant Chest Physician, Liverpool Heart and Chest Hospital
Dr Marcus Munafo, Department of Experimental Psychology, University of Bristol
Trish Jones, Smoking Advisor, Liverpool Heart and Chest Hospital
Scott Bryson, Lead Pharmaceutical Public Health, NHS Greater Glasgow & Clyde Pharmacy
Dr Su Wang, Group Head of Health, Royal Mail Group

Who will be there?
VPs, Directors, Heads and Managers of:
Smoking Cessation/Anti- Smoking Products
Outcomes Research
Business Development
Clinical Trials
Drug Delivery
Product development
Marketing/Sales
Pricing
Product Management
Regulator Organisers
Clinical Pharmacology
Projected Management
Scientific Affairs
Healthcare Professionals

Weblink: www.visiongain.com